Rinvoq scores well in Phase III ankylosing spondylitis study

AbbVie (NYSE: ABBV) yesterday announced positive top-line results from the first of two studies of the Phase III SELECT-AXIS 2 clinical trial evaluating the efficacy and safety of Rinvoq (upadacitinib; 15mg, once daily) in patients with active ankylosing spondylitis (AS) who had an inadequate response to biologic DMARD therapy.

In this study, Rinvoq met its primary endpoint of Assessment in SpondyloArthritis International Society (ASAS) 40 response and all ranked secondary endpoints at week 14. Significantly more Rinvoq-treated patients achieved ASAS40 response at week 14 compared to placebo (45% versus 18%; p<0.0001).

AbbVie shares traded at as much as $111.56, up 2.1%, yesterday.